Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

Publication | Open Access

DOI Full Paper Access

142

Citations

References

2015

Year

José Ramón Arribas, Pierre‐Marie Girard, Roland Landman, Judit Pich, Josep Mallolas, Maria Martínez‐Rebollar, Francisco Zamora, Vicente Estrada, Manuel Crespo, Daniel Podzamczer,

The Lancet Infectious Diseases

Hiv/aids CounsellingHuman RetrovirusAntiviral Drug DevelopmentAntiviral TherapyVirologyDual TreatmentHiv-1 Viral SuppressionPharmacotherapyNon-inferiority TrialAntiviral DrugHivMedicine